148 related articles for article (PubMed ID: 38494800)
41. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study).
Kataoka K; Tsushima T; Mizusawa J; Hironaka S; Tsubosa Y; Kii T; Shibuya Y; Chin K; Katayama H; Kato K; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2015 May; 45(5):494-8. PubMed ID: 25646357
[TBL] [Abstract][Full Text] [Related]
42. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract][Full Text] [Related]
43. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
45. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
46. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
Takahari D; Nakayama I
Int J Clin Oncol; 2023 Nov; 28(11):1431-1441. PubMed ID: 37500970
[TBL] [Abstract][Full Text] [Related]
47. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T; Sakai H; Ikeda S; Cheng Y; Kasahara K; Sato Y; Nakahara Y; Takeda M; Kaneda H; Zhang H; Maemondo M; Minato K; Hisada T; Misumi Y; Satouchi M; Hotta K; Li A; Oukessou A; Lu S
Int J Clin Oncol; 2022 Apr; 27(4):695-706. PubMed ID: 35182247
[TBL] [Abstract][Full Text] [Related]
48. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
50. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
51. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
52. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
53. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
54. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
J Clin Oncol; 2022 Oct; 40(28):3323-3343. PubMed ID: 35816668
[TBL] [Abstract][Full Text] [Related]
55. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
[TBL] [Abstract][Full Text] [Related]
57. Palliative chemotherapy for recurrent and metastatic esophageal cancer.
Grünberger B; Raderer M; Schmidinger M; Hejna M
Anticancer Res; 2007; 27(4C):2705-14. PubMed ID: 17695436
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
[TBL] [Abstract][Full Text] [Related]
60. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
